74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Insulet Corp
Closed
Sector Healthcare
282.6 -1.94
Overview
Share price change
24h
Min
279.85
Max
283.42
Income | -111M 78M |
|---|---|
Sales | -116M 373M |
P/E Sector Avg | 48.327 73.394 |
EPS | 0.9 |
Profit margin | 20.8 |
Employees | 3,000 |
EBITDA | 35M 117M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +13.68 upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | 398M 20B |
|---|---|
Previous open | 284.54 |
Previous close | 282.6 |
News Sentiment
By Acuity
17%
83%
19 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Bearish Evidence
Insulet Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Insulet Corp Forecast
Price Target
By TipRanks
13.68% upside
12 Months Forecast
Average 321.5 USD 13.68%
High 355 USD
Low 290 USD
Based on 15 Wall Street analysts offering 12 month price targets forInsulet Corp - Dist in the last 3 months.
Sentiment
By Acuity
19 / 393 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Insulet Corp
Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.
